Indications and Outcomes of the Osteoplastic Flap Procedure With or Without Obliteration
Author Department
Surgery
Document Type
Article, Peer-reviewed
Publication Date
7-2020
Abstract
Objective: To describe the osteoplastic approach and to perform a systematic review of the indications and outcomes of the osteoplastic flap procedure for frontal sinus surgeries with or without obliteration.
Data sources: PubMed, Medline, Google Scholar, and Cochrane databases.
Review methods: All published studies in the English language on the osteoplastic flap with or without obliteration were identified from 1905 to 2018. All studies with <20 patients were excluded. The number of patients, technique, indications, follow-up period, symptom relief, revision rates, and complications were recorded and analyzed.
Results: A systematic review yielded 25 series containing 1374 patients for analysis. Indications for surgery included chronic frontal sinusitis, mucoceles, fractures or traumas, osteomas, neoplasms, and cerebrospinal fluid leak. The mean follow-up period ranged from 12.8 to 144 months. The percentage of patients needing revisions for frontal sinus disease was 6.2%. There was a high rate of symptomatic improvement (85.0%) and a low rate of major complications (0.7%). However, minor complications occurred in 19.4% of patients.
Conclusion: The osteoplastic flap with or without obliteration has many indications. In an era where endoscopic technique provides excellent access to the frontal sinuses, external approaches remain a useful adjunct, and/or salvage technique. In experienced hands, the osteoplastic flap can yield excellent long-term clinical results, with low rates of complications. Regardless of the surgical approach, long-term follow-up is necessary due to the recurrent nature of frontal sinus disease.
Recommended Citation
Lee YH, Lee JY, Lawson W. Indications and Outcomes of the Osteoplastic Flap Procedure With or Without Obliteration. J Craniofac Surg. 2020 Jul 7. doi: 10.1097/SCS.0000000000006717. Epub ahead of print.
PMID
32649533